Fabry disease Trials in Birmingham, United States
Conditions / Fabry disease / Birmingham, United States
Fabry disease is a medical condition with active clinical research programs worldwide.
19 total trials for this combination
Showing top 10 of 19 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03425539 | Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease | COMPLETED | PHASE3 |
| NCT03566017 | Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease | COMPLETED | PHASE3 |
| NCT00196742 | Fabry Disease Registry & Pregnancy Sub-registry | RECRUITING | — |
| NCT03737214 | A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05280548 | A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05206773 | A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT00081497 | A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease | COMPLETED | PHASE4 |
| NCT00196742 | Fabry Disease Registry & Pregnancy Sub-registry | RECRUITING | — |
| NCT00074984 | A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease | COMPLETED | PHASE4 |
| NCT02795676 | Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function | COMPLETED | PHASE3 |